Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02152670 · ClinicalTrials.gov registry record · NA
Understanding Dopamine Mechanisms in Cocaine Addiction Using AMPT and Methylphenidate With [11C]RAC/[11C]PHNO PET
A NA study, sponsored by Yale University.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT02152670: Clinical Trial NA study, sponsored by Yale University.
NCT02152670 is a NA study that was terminated before completion, run by Yale University. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02152670, a NA study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
Studies using positron emission tomography (PET) have been used with great success in demonstrating specific abnormalities in several facets of dopaminergic system function in human populations (Narendran and Martinez 2009). Among the first, most consistent, and broadly replicated of such findings in drug- (including cocaine) dependent individuals has been the reduction in subcortical (striatal) D2/3 receptors as imaged, most commonly, by the reversible, non-selective, D2/3 receptor antagonist radiotracer, \[11C\]raclopride. Certain dissociations on D2/3 availability by radioligand (\[11C\]raclopride vs. \[11C\]PHNO) and by brain region (striatum vs. SN; terminal vs. somatodendritic, respectively) are poorly understood in relationship to prior antagonist tracer results. In the current study the investigators will use pharmacological interventions (AMPT and methylphenidate) with both antagonist and agonist radiotracers to experimentally reconcile these discordant findings and clarify potential mechanistic inter-relationships.
Primary Outcome
BPND is a measure of dopamine receptor availability
Interventions
- DRUG Methylphenidate
- DRUG Alpha Methyl Para Tyrosine (AMPT)
- OTHER [11C]PHNO
- OTHER [11C]raclopride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-05 |
| Est. Completion | 2014-06-09 |
| Phase | NA |
Why NCT02152670 stopped before completion
NCT02152670 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 4 interventions - of which Methylphenidate is the first listed.
NCT02152670 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02152670 about?
NCT02152670 is a clinical study titled "Understanding Dopamine Mechanisms in Cocaine Addiction Using AMPT and Methylphenidate With [11C]RAC/[11C]PHNO PET". Studies using positron emission tomography (PET) have been used with great success in demonstrating specific abnormalities in several facets of dopaminergic system function in human populations (Narendran and Martinez 2009). Among the first, most consistent, and broadly replicated of such findings i...
What is the current status of trial NCT02152670?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2014-05. Estimated completion is 2014-06-09.
What interventions are being tested in trial NCT02152670?
The interventions under investigation include: Methylphenidate (DRUG), Alpha Methyl Para Tyrosine (AMPT) (DRUG), [11C]PHNO (OTHER), [11C]raclopride (OTHER).
Who is sponsoring clinical trial NCT02152670?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02152670's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia